What is Cohance Lifesciences Ltd's PE ratio?

Cohance Lifesciences Ltd trades at a P/E ratio of 80.90.

What is Cohance Lifesciences Ltd's market cap?

Cohance Lifesciences Ltd's market capitalisation is ₹15,957 Cr.

When are Cohance Lifesciences Ltd's next results?

Cohance Lifesciences Ltd's next earnings date is 5 Aug '26.

What is Cohance Lifesciences Ltd's ROE?

Cohance Lifesciences Ltd's return on equity (ROE) is 7.0%.

What sector is Cohance Lifesciences Ltd in?

Cohance Lifesciences Ltd (COHANCE) is classified in the Healthcare sector (Pharmaceuticals).

Healthcare · Pharmaceuticals

Cohance Lifesciences Ltd (COHANCE)

₹417.10

Mkt cap

₹15,957 Cr

P/E ratio

80.90

P/B

4.09

Div yield

0.00%

ROE

7.04%

ROCE

8.35%

EPS (TTM)

₹5.16

Book value

₹102

52W range

280–1,083

Sector

Healthcare

Hyderabad based CDMO company that offers services to leading global pharmaceutical and fine chemical majors in their NCE development endeavours. From process research & development to late-stage clinical and commercial manufacturing we are committed to provide customers with products fulfilling customer needs and expectations. [1]

NSE COHANCEBSE 543064www.cohance.com

Health check

Cautious

ValuationExpensive

ProfitabilityWeak

GrowthHigh

TechnicalsBearish

52-week range

−61.50% from high

₹417

₹280+49.02% from low₹1,083

Current

₹417.10

Prev close

₹425.00

Day

−1.86%

Price performance

−1.86%

−7.46%

−8.94%

+15.83%

+4.38%

−61.98%

YTD

−19.53%

Financials

F

Revenue, profit & margin

P/E ratio

80.9×

COHANCE is 138% above the sector median of 34.0×

COHANCE80.9×

Sector median34.0×

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	369.36	347.55	231.05	219.82	252.93	488.08	603.77	676.23	840.42	549.31	555.57	544.55	619.12
Expenses	197.50	180.59	133.09	153.74	179.58	362.98	398.40	438.86	611.20	437.30	434.62	449.20	520.44
Operating Profit	171.86	166.96	97.96	66.08	73.35	125.10	205.37	237.37	229.22	112.01	120.95	95.35	98.68
OPM %	46.53%	48.04%	42.40%	30.06%	29.00%	25.63%	34.01%	35.10%	27.27%	20.39%	21.77%	17.51%	15.94%
Other Income	11.40	10.67	19.84	14.34	17.05	19.41	16.19	21.56	-3.73	6.07	15.60	1.30	-18.35
Interest	5.03	1.15	0.50	2.16	2.30	10.20	9.61	10.80	10.45	10.18	8.76	9.11	9.19
Depreciation	12.02	12.54	11.89	12.79	17.25	31.28	37.79	43.56	54.17	45.14	44.02	46.94	51.23
Profit before tax	166.21	163.94	105.41	65.47	70.85	103.03	174.16	204.57	160.87	62.76	83.77	40.60	19.91
Tax %	25.41%	26.44%	24.51%	28.59%	24.67%	26.85%	20.62%	24.97%	27.18%	26.07%	20.75%	28.52%	58.26%
Net Profit	123.97	120.59	79.56	46.75	53.37	75.37	138.24	153.48	117.15	46.40	66.39	29.02	8.31
EPS in Rs	4.87	4.74	3.13	1.84	2.10	2.96	5.44	6.01	4.73	1.28	1.94	0.96	0.51
Raw PDF

Earnings

EResults dates & reactions

Next results

5 Aug '26scheduled

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

Avg earnings-day move −1.56% · closed higher next day 10 of last 22

	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26†	Q3FY26	Q4FY26
Broadcast	26 May '23	8 Aug '23◦	10 Nov '23◦	6 Feb '24◦	9 Aug '24◦	13 Nov '24◦	13 Feb '25◦	28 May '25◦	13 Aug '25◦	17 Jul '26	12 Feb '26◦	12 May '26◦
Earnings day	+0.28%	+0.59%	−0.47%	+1.16%	+4.69%	+0.98%	−2.71%	−3.81%	−7.32%	+0.03%	−10.02%	−5.85%
+1 day	+0.53%	+2.59%	−1.81%	+3.32%	+3.52%	+1.48%	−0.06%	−5.51%	−9.00%	+2.03%	−12.59%	−8.14%
+5 days	+0.55%	+6.38%	+3.33%	+6.68%	+0.19%	+2.50%	+9.50%	−4.07%	−10.28%	−3.79%	−12.93%	−13.31%
+15 days	+2.14%	+4.72%	+14.74%	+4.63%	+12.58%	+3.46%	+3.26%	−10.65%	+2.73%	—	−19.44%	−12.25%
+30 days	+2.23%	+8.23%	+20.23%	+2.71%	+21.96%	−9.79%	−2.27%	−10.18%	−11.12%	—	−11.06%	−5.49%
Filing	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL

Corporate actions

CLast 6 months

No recent corporate actions

Dividends, splits, and bonuses in the last six months show up here.

Shareholding

Sas of Jun 2026

57.49%Promoter

Promoters57.49%

FIIs6.50%0.91

DIIs20.09%1.70

Public15.92%0.81

Government0.01%

Ownership trend

Peers

P8 companies

Valuation vs quality

P/E × ROCE · bubble = market cap

Name	CMP	P/E	Mkt Cap	Div Yld	NP Qtr	Qtr Profit Var	Sales Qtr	Qtr Sales Var	ROCE
Sun Pharma.Inds.	₹1,941.10	37.48	4,65,735	0.82%	2,710	+13.58%	14,612	+12.76%	20.53%
Divi's Lab.	₹7,248.50	73.36	1,92,425	0.41%	751	+13.44%	2,831	+9.52%	21.97%
Torrent Pharma.	₹4,961.50	86.11	1,88,720	0.77%	364	−20.58%	4,197	+41.84%	15.19%
Cipla	₹1,410.60	31.84	1,13,955	0.92%	786	−39.19%	7,119	+2.33%	15.49%
Zydus Lifesci.	₹1,108.70	20.38	1,10,593	0.09%	1,341	+21.92%	7,587	+16.22%	21.14%
Lupin	₹2,370.50	19.06	1,08,387	0.76%	1,469	+101.49%	7,475	+31.89%	29.93%
Mankind Pharma	₹2,507.20	51.44	1,03,546	0.04%	559	+34.23%	3,443	+11.81%	13.53%
Cohance Life	₹417.10	80.86	15,957	0.00%	8	−86.64%	619	−26.33%	8.35%
Median: 157 Co.	₹432.05	34.03	1,978	0.10%	15	+28.10%	176	+17.66%	15.10%

Filings

D

Annual reports6

Financial Year 2025bse Financial Year 2024bse Financial Year 2023bse Financial Year 2022bse Financial Year 2021bse Financial Year 2020bse

Credit ratings6

Rating update 3 Dec 2025fitch Rating update 26 Aug 2025crisil Rating update 23 Jul 2025care Rating update 28 May 2025crisil Rating update 27 Feb 2025crisil Rating update 29 Nov 2024crisil

Announcements5

Allotment Of Equity Shares Pursuant To Exercise Of Stock Options And Grant Of Stock Options To Certain Eligible Employees Of The Company 1d - 23 July 2026 ESOP approvals: 1.97 crore ESOP 2026 options, 1.74 lakh ESOP 2023 options, 30,190 shares allotted.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 1d Board Meeting Intimation for Considering The Unaudited Financial Results (Standalone And Consolidated) Of The Company, For The Quarter Ended 30 June 2026 1d - Board meets 5 August 2026 to approve Q1 FY27 unaudited standalone and consolidated results.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 Jul Closure of Trading Window 26 Jun